These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37079393)

  • 21. Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
    Comeaux CA; Bart S; Bastian AR; Klyashtornyy V; De Paepe E; Omoruyi E; van der Fits L; van Heesbeen R; Heijnen E; Callendret B; Sadoff J
    J Infect Dis; 2024 Jan; 229(1):19-29. PubMed ID: 37433021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
    Evans TG; Bussey L; Eagling-Vose E; Rutkowski K; Ellis C; Argent C; Griffin P; Kim J; Thackwray S; Shakib S; Doughty J; Gillies J; Wu J; Druce J; Pryor M; Gilbert S
    Lancet Infect Dis; 2022 Jun; 22(6):857-866. PubMed ID: 35305317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.
    Russell MS; Thulasi Raman SN; Gravel C; Zhang W; Pfeifle A; Chen W; Van Domselaar G; Safronetz D; Johnston M; Sauve S; Wang L; Rosu-Myles M; Cao J; Li X
    Front Immunol; 2021; 12():747866. PubMed ID: 34603336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.
    Díez-Domingo J; Sáez-Llorens X; Rodriguez-Weber MA; Epalza C; Chatterjee A; Chiu CH; Lin CY; Berry AA; Martinón-Torres F; Baquero-Artigao F; Langley JM; Ramos Amador JT; Domachowske JB; Huang LM; Chiu NC; Esposito S; Moris P; Lien-Anh Nguyen T; Nikic V; Woo W; Zhou Y; Dieussaert I; Leach A; Gonzalez Lopez A; Vanhoutte N
    J Infect Dis; 2023 May; 227(11):1293-1302. PubMed ID: 36484484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein.
    Torrey HL; Kaliaperumal V; Bramhecha Y; Weir GM; Falsey AR; Walsh EE; Langley JM; Schepens B; Saelens X; Stanford MM
    Hum Vaccin Immunother; 2020 Sep; 16(9):2007-2017. PubMed ID: 32530723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.
    Stephens LM; Ross KA; McLellan JS; Narasimhan B; Varga SM
    J Virol; 2022 Nov; 96(22):e0150222. PubMed ID: 36314826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
    Olszewska W; Suezer Y; Sutter G; Openshaw PJ
    Vaccine; 2004 Nov; 23(2):215-21. PubMed ID: 15531040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
    Falloon J; Ji F; Curtis C; Bart S; Sheldon E; Krieger D; Dubovsky F; Lambert S; Takas T; Villafana T; Esser MT
    Vaccine; 2016 May; 34(25):2847-54. PubMed ID: 27102821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
    Papi A; Ison MG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Campora L; Dezutter N; de Schrevel N; Fissette L; David MP; Van der Wielen M; Kostanyan L; Hulstrøm V;
    N Engl J Med; 2023 Feb; 388(7):595-608. PubMed ID: 36791160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children.
    McFarland EJ; Karron RA; Muresan P; Cunningham CK; Perlowski C; Libous J; Oliva J; Jean-Philippe P; Moye J; Schappell E; Barr E; Rexroad V; Fearn L; Cielo M; Wiznia A; Deville JG; Yang L; Luongo C; Collins PL; Buchholz UJ
    J Infect Dis; 2020 Jun; 221(12):2050-2059. PubMed ID: 32006006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
    Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
    Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
    Buchholz UJ; Cunningham CK; Muresan P; Gnanashanmugam D; Sato P; Siberry GK; Rexroad V; Valentine M; Perlowski C; Schappell E; Thumar B; Luongo C; Barr E; Aziz M; Yogev R; Spector SA; Collins PL; McFarland EJ; Karron RA;
    J Infect Dis; 2018 Apr; 217(9):1338-1346. PubMed ID: 29509929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
    Ahmad A; Eze K; Noulin N; Horvathova V; Murray B; Baillet M; Grey L; Mori J; Adda N
    N Engl J Med; 2022 Feb; 386(7):655-666. PubMed ID: 35172056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.
    Taylor G; Thom M; Capone S; Pierantoni A; Guzman E; Herbert R; Scarselli E; Napolitano F; Giuliani A; Folgori A; Colloca S; Cortese R; Nicosia A; Vitelli A
    Sci Transl Med; 2015 Aug; 7(300):300ra127. PubMed ID: 26268314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial.
    Sáez-Llorens X; Norero X; Mussi-Pinhata MM; Luciani K; de la Cueva IS; Díez-Domingo J; Lopez-Medina E; Epalza C; Brzostek J; Szymański H; Boucher FD; Cetin BS; De Leon T; Dinleyici EC; Gabriel MÁM; Ince T; Macias-Parra M; Langley JM; Martinón-Torres F; Rämet M; Kuchar E; Pinto J; Puthanakit T; Baquero-Artigao F; Gattinara GC; Arribas JMM; Ramos Amador JT; Szenborn L; Tapiero B; Anderson EJ; Campbell JD; Faust SN; Nikic V; Zhou Y; Pu W; Friel D; Dieussaert I; Lopez AG; McPhee R; Stoszek SK; Vanhoutte N
    J Infect Dis; 2024 Jan; 229(1):95-107. PubMed ID: 37477875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
    Stuart ASV; Virta M; Williams K; Seppa I; Hartvickson R; Greenland M; Omoruyi E; Bastian AR; Haazen W; Salisch N; Gymnopoulou E; Callendret B; Faust SN; Snape MD; Heijnen E
    J Infect Dis; 2022 Dec; 227(1):71-82. PubMed ID: 36259542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
    Wilson E; Goswami J; Baqui AH; Doreski PA; Perez-Marc G; Zaman K; Monroy J; Duncan CJA; Ujiie M; Rämet M; Pérez-Breva L; Falsey AR; Walsh EE; Dhar R; Wilson L; Du J; Ghaswalla P; Kapoor A; Lan L; Mehta S; Mithani R; Panozzo CA; Simorellis AK; Kuter BJ; Schödel F; Huang W; Reuter C; Slobod K; Stoszek SK; Shaw CA; Miller JM; Das R; Chen GL;
    N Engl J Med; 2023 Dec; 389(24):2233-2244. PubMed ID: 38091530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.